Sandbox Reserved 1176

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 32: Line 32:
====Leu310====
====Leu310====
-
<scene name='72/721548/L310/3'>Leu310</scene> is crucial for interactions with the G alpha subunit by interacting with Arg167 of the conserved <scene name='72/721548/Dery_motif/1'>D/ERY motif</scene><ref name="SPGP"/> . When Leu310 was substituted with alanine, Arg167 was able to form a stabilizing hydrogen bonding network with Asn257, Ser164 and Gly306, which oriented Arg167 in a position that was unfavorable for contacting the G alpha subunit. When residue 310 was converted back to leucine, this hydrogen-bonding network was sterically unfavorable (Figure 3) and Arg167 interacted with the G alpha subunit leading to the transduction of several different signals involved in leptin signlaing, dopamine regulation, etc. <ref name="SPGP"/> <ref name="Mice"/><ref name="cancer"/><ref name="Schizophrenia"/>
+
<scene name='72/721548/L310/3'>Leu310</scene> is crucial for interactions with the G alpha subunit through its interactions with Arg167 of the conserved <scene name='72/721548/Dery_motif/1'>D/ERY motif</scene><ref name="SPGP"/> . When Leu310 was substituted with alanine, Arg167 was able to form a stabilizing hydrogen bonding network with Asn257, Ser164 and Gly306, which oriented Arg167 in a position that was unfavorable for contacting the G alpha subunit. When residue 310 was converted back to leucine, this hydrogen-bonding network was sterically unfavorable (Figure 3) and Arg167 interacted with the G alpha subunit leading to the transduction of several different signals involved in leptin signlaing, dopamine regulation, etc. <ref name="SPGP"/> <ref name="Mice"/><ref name="cancer"/><ref name="Schizophrenia"/>
.
.

Revision as of 01:39, 22 April 2016

An interactive view of the class A GPCR, NTSR1 (blue). This protein gets its activity from binding to the 13 amino acid ligand, NTS (red).

Drag the structure with the mouse to rotate

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
  3. 3.0 3.1 3.2 3.3 Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology. 2010 Jun;58(8):1199-205. doi:, 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6. PMID:20211191 doi:http://dx.doi.org/10.1016/j.neuropharm.2010.02.015
  4. 4.0 4.1 4.2 Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006 Oct;27(10):2445-60. Epub 2006 Aug 2. PMID:16887236 doi:http://dx.doi.org/10.1016/j.peptides.2006.04.030
  5. 5.0 5.1 5.2 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. PMID:22596253 doi:http://dx.doi.org/10.1038/nrd3702
Personal tools